The Centers for Disease Control and Prevention’s (CDC) director confirmed Sunday that the Food and Drug Administration (FDA) is discussing how to streamline the authorization of an Omicron-specific COVID-19 vaccine. During an interview with ABC News, Director Rochelle Walensky said that vaccine makers Pfizer, Moderna, and Johnson & Johnson have told the agency that “they can all do this fairly quickly within three months … but then you have FDA approval.” The FDA, she added, is “already in conversations about streamlining the authorization of this, of an Omicron-specific vaccine, partially because much of the vaccine is actually exactly the same and really, it would just be that mRNA code that would have to change.” Without elaborating on the nature of the discussions, Walensky said that “those conversations are ongoing, and certainly, [the] FDA will move swiftly and CDC will move swiftly right thereafter.” Should an Omicron-specific vaccine be developed, it’s …